Literature DB >> 6203843

The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

J Drews.   

Abstract

Therapeutic agents capable of stimulating immune responses could be of great value in the prophylaxis and treatment of infectious diseases. Three classes of compounds, each representing a separate approach to the goal of immune stimulation, are discussed with respect to recent experimental and clinical findings. The action of microbial structures and their derivatives can be understood on the basis of "acquired cellular immunity", a phenomenon first described in connection with infections by mycobacteria and other intracellular organisms. In contrast, there is hardly a common denominator for synthetic compounds which are currently used as immune-stimulatory agents. Substances which influence purine metabolism in lymphocytes on the one hand and histamine H2 blockers such as cimetidine on the other hand seem to represent the most promising developments in this field to date. Products of immune cells such as transfer factor and lymphokines form the third and possibly most important group of immune-stimulating agents. Current experimental and clinical trends in this field are briefly described. It is suggested that the delineation of the mechanism of action of lymphokines will open the door to the identification or synthesis of artificial agonists and antagonists as has been the case in the pharmacology of the endocrine and nervous systems.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203843     DOI: 10.1007/bf01641705

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  73 in total

1.  Macrophage activation for tumor cytotoxicity: tumoricidal activity by macrophages from C3H/HeJ mice requires at least two activation stimuli.

Authors:  L P Ruco; M S Meltzer
Journal:  Cell Immunol       Date:  1978-11       Impact factor: 4.868

Review 2.  Resistance to intracellular infection.

Authors:  G B Mackaness
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

3.  Atypical mycobacterium infection treated with dialyzable leukocyte extracts: evidence for antigenic specificity.

Authors:  M R Simon; D J Salberg; J Silva; S Ganji; S Desai; B F Muller; M Palutke
Journal:  Clin Immunol Immunopathol       Date:  1981-07

4.  Metabolic defects and immunodeficiency disorders.

Authors:  R Hirschhorn
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

5.  Immunotherapy-immunomodulation.

Authors:  R Patterson; P Norman; T Van Metre
Journal:  JAMA       Date:  1982-11-26       Impact factor: 56.272

6.  Transfer factor for the prevention of varicella-zoster infection in childhood leukemia.

Authors:  R W Steele; M G Myers; M M Vincent
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

7.  The in vivo and in vitro effects of levamisole in patients with lepromatous leprosy.

Authors:  R Sher; A A Wadee; M Joffe; S H Kok; F M Imkamp; I W Simson
Journal:  Int J Lepr Other Mycobact Dis       Date:  1981-06

8.  Human leukocyte interferon for the treatment of varicella in children with cancer.

Authors:  A M Arvin; J H Kushner; S Feldman; R L Baehner; D Hammond; T C Merigan
Journal:  N Engl J Med       Date:  1982-04-01       Impact factor: 91.245

9.  Modulation of human T lymphocyte functions by isoprinosine.

Authors:  A Rey; D Cupissol; C Thierry; C Esteve; B Serrou
Journal:  Int J Immunopharmacol       Date:  1983

10.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1964-07-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Thymomodulin: biological properties and clinical applications.

Authors:  N M Kouttab; M Prada; P Cazzola
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Effect of free or liposome-encapsulated muramyl dipeptide on uptake and intracellular survival of Listeria monocytogenes in mouse peritoneal macrophages in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

4.  Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

Authors:  P M Melissen; W van Vianen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.